Fabtech Technologies Limited (FTL), a leading provider of pharmaceutical and life sciences infrastructure solutions, has secured a contract valued at ₹31.23 crore for the critical internal infrastructure package of a new veterinary vaccine manufacturing facility in Botswana. The project marks another important milestone in the company’s growing footprint across Africa and reinforces its position as a key infrastructure partner for healthcare, biotechnology and vaccine manufacturing projects in emerging markets.
The upcoming facility is expected to play a significant role in strengthening veterinary healthcare capabilities across Southern Africa by expanding regional vaccine production capacity. The project aligns with ongoing efforts by several African nations to establish local manufacturing ecosystems for vaccines and biological products, reducing dependence on imports while enhancing healthcare resilience and food security.
Under the contract, Fabtech will be responsible for delivering advanced Good Manufacturing Practice (GMP)-compliant infrastructure, including specialized heating, ventilation and air-conditioning (HVAC) systems, clean utility networks and critical mechanical, electrical and plumbing (MEP) services. The integrated infrastructure package is being designed to meet international pharmaceutical manufacturing standards and support efficient, safe and scalable vaccine production.
The facility is expected to contribute to the region’s ability to address animal health challenges through locally manufactured vaccines, which are critical to protecting livestock populations and ensuring agricultural productivity. By supporting veterinary healthcare infrastructure, the project also contributes to broader economic and food security objectives across the region.
Fabtech’s involvement extends beyond the delivery of core infrastructure. The company will provide a comprehensive platform that enables future expansion and operational flexibility, supporting the long-term development of advanced vaccine and biologics manufacturing capabilities. The infrastructure being deployed is designed to accommodate evolving production requirements and future technological advancements within the life sciences sector.
Africa has emerged as a key growth market for pharmaceutical and biotechnology investments, with governments and private sector stakeholders increasingly prioritizing local manufacturing capabilities. As demand rises for vaccine self-sufficiency and resilient healthcare supply chains, investments in modern manufacturing facilities are expected to accelerate across the continent.
For Fabtech, the Botswana project represents another step in its strategy of supporting healthcare infrastructure development in high-growth markets. The company has established expertise in delivering complex pharmaceutical, biotechnology and life sciences facilities that meet stringent regulatory requirements while enabling efficient commercial operations.
The latest contract further strengthens Fabtech’s credentials as a trusted partner for pharmaceutical and vaccine manufacturing projects worldwide. It also reflects the growing recognition of the company’s engineering capabilities and project execution expertise within the global life sciences industry. As countries continue to invest in healthcare preparedness and local production capabilities, Fabtech remains focused on delivering infrastructure solutions that help manufacturers meet global standards while addressing regional healthcare needs.
Fabtech Technologies Limited is a provider of integrated infrastructure solutions for the pharmaceutical, biotechnology and life sciences industries. The company specializes in engineering, cleanroom systems, HVAC solutions, utilities and turnkey infrastructure projects that support world-class manufacturing facilities across global markets.
